Breaking News Bar

Business News and Information

Eli Lilly ends deal with NextCure worth up to $1.4B for the local biotech

Under the deal, inked in November 2018, NextCure gave Eli Lilly access to its proprietary platform for research aimed at developing and commercializing new cancer therapies.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
bottom clear